A hyperspectral method to assay the microphysiological fates of nanomaterials in histological samples

  1. Elliott D SoRelle
  2. Orly Liba
  3. Jos L Campbell
  4. Roopa Dalal
  5. Cristina L Zavaleta
  6. Adam de la Zerda  Is a corresponding author
  1. Stanford University, United States
  2. RMIT University, Australia

Abstract

Nanoparticles are used extensively as biomedical imaging probes and potential therapeutic agents. As new particles are developed and tested in vivo, it is critical to characterize their biodistribution profiles. We demonstrate a new method that uses adaptive algorithms for analysis of hyperspectral dark-field images to study the interactions between tissues and administered nanoparticles. This non-destructive technique quantitatively identifies particles in ex vivo tissue sections and enables detailed observations of accumulation patterns arising from organ-specific clearance mechanisms, particle size, and the molecular specificity of nanoparticle surface coatings. Unlike nanoparticle uptake studies with electron microscopy, this method is tractable for imaging large fields of view. Adaptive hyperspectral image analysis achieves excellent detection sensitivity and specificity and is capable of identifying single nanoparticles. Using this method, we collected the first data on the sub-organ distribution of several types of gold nanoparticles in mice and observed localization patterns in tumors.

Article and author information

Author details

  1. Elliott D SoRelle

    Molecular Imaging Program at Stanford, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3362-1028
  2. Orly Liba

    Molecular Imaging Program at Stanford, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Jos L Campbell

    Ian Potter NanoBioSensing Facility, NanoBiotechnology Research Laboratory, School of Science, RMIT University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  4. Roopa Dalal

    Department of Ophthalmology, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Cristina L Zavaleta

    Molecular Imaging Program at Stanford, Stanford University, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Adam de la Zerda

    Molecular Imaging Program at Stanford, Stanford University, Stanford, United States
    For correspondence
    adlz@stanford.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

Claire Giannini Fund

  • Adam de la Zerda

Stanford Bio-X Interdisciplinary Initiative Seed Grant

  • Adam de la Zerda

U.S. Air Force (FA9550-15-1-0007)

  • Adam de la Zerda

National Institutes of Health (NIH DP50D012179)

  • Adam de la Zerda

Damon Runyon Cancer Research Foundation (DFS# 06-13)

  • Adam de la Zerda

Susan G. Komen (SAC15-00003)

  • Adam de la Zerda

Mary Kay Foundation (017-14)

  • Adam de la Zerda

Donald E. and Delia B. Baxter Foundation

  • Adam de la Zerda

Skippy Frank Foundation

  • Adam de la Zerda

Center for Cancer Nanotechnology Excellence and Translation (CCNE-T U54CA151459)

  • Adam de la Zerda

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments in this study were performed in compliance with IACUC guidelines and with the Stanford University Animal Studies Committee's Guidelines for the Care and Use of Research Animals (APLAC Protocol #27499 and #29179).

Copyright

© 2016, SoRelle et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,617
    views
  • 439
    downloads
  • 26
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Elliott D SoRelle
  2. Orly Liba
  3. Jos L Campbell
  4. Roopa Dalal
  5. Cristina L Zavaleta
  6. Adam de la Zerda
(2016)
A hyperspectral method to assay the microphysiological fates of nanomaterials in histological samples
eLife 5:e16352.
https://doi.org/10.7554/eLife.16352

Share this article

https://doi.org/10.7554/eLife.16352

Further reading

    1. Cancer Biology
    2. Stem Cells and Regenerative Medicine
    Alison G Barber, Cynthia M Quintero ... Tannishtha Reya
    Research Article

    Despite advances in therapeutic approaches, lung cancer remains the leading cause of cancer-related deaths. To understand the molecular programs underlying lung cancer initiation and maintenance, we focused on stem cell programs that are normally extinguished with differentiation but can be reactivated during oncogenesis. Here, we have used extensive genetic modeling and patient-derived xenografts (PDXs) to identify a dual role for Msi2: as a signal that acts initially to sensitize cells to transformation, and subsequently to drive tumor propagation. Using Msi reporter mice, we found that Msi2-expressing cells were marked by a pro-oncogenic landscape and a preferential ability to respond to Ras and p53 mutations. Consistent with this, genetic deletion of Msi2 in an autochthonous Ras/p53-driven lung cancer model resulted in a marked reduction of tumor burden, delayed progression, and a doubling of median survival. Additionally, this dependency was conserved in human disease as inhibition of Msi2 impaired tumor growth in PDXs. Mechanistically, Msi2 triggered a broad range of pathways critical for tumor growth, including several novel effectors of lung adenocarcinoma. Collectively, these findings reveal a critical role for Msi2 in aggressive lung adenocarcinoma, lend new insight into the biology of this disease, and identify potential new therapeutic targets.

    1. Cancer Biology
    Rui Vasco Simoes, Rafael Neto Henriques ... Noam Shemesh
    Research Article

    Glioblastomas are aggressive brain tumors with dismal prognosis. One of the main bottlenecks for developing more effective therapies for glioblastoma stems from their histologic and molecular heterogeneity, leading to distinct tumor microenvironments and disease phenotypes. Effectively characterizing these features would improve the clinical management of glioblastoma. Glucose flux rates through glycolysis and mitochondrial oxidation have been recently shown to quantitatively depict glioblastoma proliferation in mouse models (GL261 and CT2A tumors) using dynamic glucose-enhanced (DGE) deuterium spectroscopy. However, the spatial features of tumor microenvironment phenotypes remain hitherto unresolved. Here, we develop a DGE Deuterium Metabolic Imaging (DMI) approach for profiling tumor microenvironments through glucose conversion kinetics. Using a multimodal combination of tumor mouse models, novel strategies for spectroscopic imaging and noise attenuation, and histopathological correlations, we show that tumor lactate turnover mirrors phenotype differences between GL261 and CT2A mouse glioblastoma, whereas recycling of the peritumoral glutamate-glutamine pool is a potential marker of invasion capacity in pooled cohorts, linked to secondary brain lesions. These findings were validated by histopathological characterization of each tumor, including cell density and proliferation, peritumoral invasion and distant migration, and immune cell infiltration. Our study bodes well for precision neuro-oncology, highlighting the importance of mapping glucose flux rates to better understand the metabolic heterogeneity of glioblastoma and its links to disease phenotypes.